Corrigendum to "Efficacy of the first-line immune checkpoint inhibitor plus chemotherapy for gastroesophageal cancer: A meta-analysis of phase III trials including unreported PD-L1 subgroups" [Cancer Lett. 623, (2025) 217718]

Affiliations

¹ Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; Song-dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea.
² Song-dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea.
³ Department of Biostatistics and Computing, Yonsei University College of Medicine, Seoul, South Korea.
⁴ Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
⁵ Department of Biostatistics and Computing, Yonsei University College of Medicine, Seoul, South Korea; Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, South Korea.
⁶ Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; Song-dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: RHA7655@yuhs.ac.

Published Erratum

Choong-Kun Lee et al. Cancer Lett. 2025.

. 2025 Oct 10:630:217826.

doi: 10.1016/j.canlet.2025.217826. Epub 2025 Jun 3.

¹ Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; Song-dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea.
² Song-dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea.
³ Department of Biostatistics and Computing, Yonsei University College of Medicine, Seoul, South Korea.
⁴ Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
⁵ Department of Biostatistics and Computing, Yonsei University College of Medicine, Seoul, South Korea; Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, South Korea.
⁶ Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; Song-dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: RHA7655@yuhs.ac.

No abstract available

Erratum for

Efficacy of the first-line immune checkpoint inhibitor plus chemotherapy for gastroesophageal cancer: A meta-analysis of phase III trials including unreported PD-L1 subgroups.
Lee CK, Park S, Lee Y, Yun C, Hong M, Nam CM, Chung HC, Rha SY. Lee CK, et al. Cancer Lett. 2025 Jul 28;623:217718. doi: 10.1016/j.canlet.2025.217718. Epub 2025 Apr 14. Cancer Lett. 2025. PMID: 40239914